Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

$1.00

Licensing Options

Clear

Category: Multiple Myeloma

Tags: Model 17

All your purchased models will be available under your account under “Dashboards”

Disease Area (Primary)

Multiple Myeloma

Disease Area (Secondary)

–

First Developed

04/21/2024

Last Developed

–

Software Used

R (e.g., heemod, BCEA, dampack, hesim)

Model Sponsor

Academic institution

Intervention

daratumumab_lenalidomide_and_dexamethasone

Model Validation Score

– %

Coming Soon In Phase II: You will be able to pay a fee to download the CADTH Tool for your model which includes subaggregated scores.

Results

The incremental cost-effectiveness ratio (ICER) for daratumumab, lenalidomide, and dexamethasone (DRd) compared with bortezomib, lenalidomide, and dexamethasone (VRd) was US $90,364 per QALY gained. The results were sensitive to variations in survival for DRd, postprogression treatment costs, cost of hospice care, and hazard ratio for progression-free survival. The scenarios explored indicated that structural assumptions, such as the time horizon of the analysis, significantly influenced the results due to uncertainties arising from immature trial data and treatment efficacy over time. Among the various payer strategies compared, an upfront price discount for daratumumab emerged as the best approach with the lowest P-SUB at US $14,708.

Conclusion

What are the key conclusions or current applications of this model?

Source File(s)

Model:

Download Model File

Publication File:

Publication File 1:

Publication File 2:

Publication File 3:

Publication File 4:

Download Publication File

No link submitted.

Model Review

Only visible for the model owner

Summary

Validation Score

– %

Internal Comments

–

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

Model:

Model Script 2 :

Model Script 3 :

Model Script 3 :

Publication File:

Publication File 1:

Publication File 2:

Publication File 3:

Publication File 4:

Code file 1 :

Code file 2 :

Code file 3 :

Code file 4 :

Non-Model Script 1 :

Non-Model Script 2 :

Non-Model Script 3 :

Non-Model Script 4 :

Data File 1 :

Data File 2 :

Data File 3 :

Data File 4 :

Document 1 :

Document 2 :

Document 3 :

Document 4 :

Model Review

Summary

Validation Score

Internal Comments